Spis treści:
1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY

Spis załączników:
  1. Krka Group 2025 Performance Estimate.pdf2025 Krka Group performance estimatE

POLISH FINANCIAL SUPERVISION AUTHORITY

UNI - EN REPORT No 4 / 2026
Date of issue: 2026-01-29
Short name of the issuer
KRKA
Subject
2025 Krka Group Performance Estimate
Official market - legal basis
Art. 17 ust. 1 MAR
Unofficial market - legal basis
Contents of the report:
Based on the provisions of Article 26 of the Ljubljana Stock Exchange Rules, Article 158 of the Market in Financial Instruments Act and Article 17 of Regulation (EU) No 596/2014, Krka, d. d., Novo mesto (hereinafter: Krka) releases the 2025 unaudited performance estimates for the Krka Group.

The press releases with 2025 Krka Group performance estimate is attached.

This announcement will be published on the company’s website (www.krka.biz) starting from 29 January 2026, for a minimum period of 5 years.
Annexes
File Description
Krka Group 2025 Performance Estimate.pdf
Krka Group 2025 Performance Estimate.pdf		 2025 Krka Group performance estimatE

KRKA, TOVARNA ZDRAVIL D.D.
(fullname of the issuer)
KRKA Farmaceutyczny (far)
(short name of the issuer) (sector according to clasification
of the WSE in Warsow)
8501 Nove Mesto
(post code) (city)
Smarjeska 6
(street) (number)
+386 7 331 21 11 +386 7 332 15 37
(phone number) (fax)
(e-mail) (web site)
nie dotyczy
(NIP) (REGON)

SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Date Name Position / Function Signature
2026-01-29 Jože Colarič President of the Management Board and CEO
20260129_120035_1698823151_Krka_Group_2025_Performance_Estimate.pdf

Pobierz